INTRAOPERATIVE PHOTODYNAMIC THERAPY FOR METASTATIC PERITONEAL TUMORS

This review is devoted to the cytoreductive treatment of malignant tumors of the abdominal organs. The actuality of the issue is determined both by increase of the incidence of abdominal cancer in Russia and in majority of developed countries and by high rate diagnosis on late stages of disease. The methods of treatment of peritoneal carcinomatosis, based on possible effects on the secondary peritoneal tumors after surgical cytoreduction to reduce the risk of local recurrence and disease progression are described. These methods of additional intraoperative specific antitumor action include intraoperative radiation therapy, hyperthermic intraperitoneal chemotherapy, intraoperative photodynamic therapy characterized by differences in difficulty of performance, mechanisms of effect on tumor and healthy tissues, efficiency. Benefits, opportunities and possibilities of application of intraoperative photodynamic therapy (IOPDT) for secondary peritoneal tumors are described in details, the results of a number of domestic and foreign clinical studies are shown, the successful application of intraoperative photodynamic therapy in clinical oncology, which allows reducing the risk of secondary tumor lesions of the peritoneum significantly, is demonstrated. Photodynamic therapy – a method with high efficiency and almost no side effects and complications, based on the ability of photosensitizer to accumulate selectively and retain in the high proliferative tissues. The advantages of this type of treatment of patients with peritoneal carcinomatosis are a selective effect on the peritoneal carcinomatosis and on visually detected tumor tissue, high efficiency in patients with malignant tumors of the abdominal cavity and pelvis combined with surgical cytoreduction, minimal effect on normal organs and tissues of the patient, well tolerated procedure.

1. Sostoyanie onkologicheskoĭ pomoshchi naseleniyu Rossii v 2014 godu [State of cancer care in Russia in 2014]. Ed by A. D. Kaprin. V. V. Starinskii. G. V. Petrova. Мoscow: P. Hertsen Moscow Oncology Research Institute, 2015. Available at: http://www.oncology.ru/service/statistics/condition/2014.pdf (In Russian).

2. Davydov M. I., Abdikhakimov A. N., Polotskii B. E., Stilidi I. S., Ter-Avanesov M. D., Marchuk V. A. K voprosu o roli khirurgii v lechenii mestnorasprostranennogo i disseminirovannogo raka zheludka. Annals of Surgery. 2002;2:33–41. (In Russian).

3. Sugarbacker P. H., Yonemura Y. Clinical pathway for the management of respectable gastric cancer with peritoneal seedings: best palliation with a ray of hope for cure. Oncology. 2000;58:96–107.

4. Mitel’man L.Yu. Ad”yuvantnaya luchevaya terapiya raka zheludka [Adjuvant radiation therapy for gastric cancer]. Dissertation. Tomsk, 2007. (In Russian).

5. Skoropad V.Yu., Berdov B. A. Ad”yuvantnaya khimioterapiya i khimioluchevaya terapiya operabel’nogo raka zheludka: sovremennoe sostoyanie problemy. Voprosy oncologii. 2004;50 (5):524–32. (In Russian).

6. Skoropad V.Yu., Berdov B. A., Mardynsky Yu. S., Titova L. N., Pakhomenko K. V. Pre- and intraoperative radiotherapy for locally advanced gastric cancer in conjunction with extended lymph node dissection: results of phase II clinical study. Voprosy oncologii. 2004;50 (5):585–9. (In Russian).

7. Skoropad V.Yu., Berdov B. A., Mardynsky Yu. S., Titova L. N. Comparison of end-results of combined and surgical treatment of gastric cancer Voprosy oncologii. 2007;53(4):427–35. (In Russian).

8. Ogata Т., Araki K., Matsuura K., Kobayashi M., Inomata T., Yasuhiro O., et al. A 10‑year experience of intraoperative radiotherapy for gastric carcinoma and a new surgical method of creating a wider irradiation field for cases of total gastrectomy patients. Int J Radiat Oncol Biol Phys. 1995;32 (2):341–7. DOI: 10.1016/0360–3016 (94)00479–5

9. Vasilenko I. V., Sadchikov V. D., Galakhin K. A., et al. Predrak i rak zheludka [Precancer and cancer of the stomach]. Kiev: “3dorov’ya” Publ., 2001, 214 p.

10. Galakhin L. F., Kurik E. G. Lechebnyi patomorfoz zlokachestvennykh opukholei pishchevaritel’nogo trakta [Therapeutic pathomorphosis of malignant tumors of the digestive tract]. Kiev: “Kniga plyus” Publ., 2000, 175 p. (In Russian).

11. Wydmanski J., Suwinski R., Poltorak S., Maka B., Miszczyk L., Wolny E., et al. The tolerance and efficacy of preoperative chemoradiotherapy followed by gastrectomy in operable gastric cancer, a phase II study. Radiother Oncol. 2007 Feb;82 (2):132–6. DOI: 10.1016/j.radonc.2007.01.009

12. Turkin I. N. Paraaortal’naya limfodissektsiya pri rake zheludka [Paraaortic lymph node dissection in gastric cancer]. Dissertation. Moscow, 2003. (In Russian).

13. Elias D. M. Peritoneal carcinomatosis or liver metastases from colorectal cancer: similar standards for a curative surgery? Ann Surg Oncol. 2004 Feb;11 (2):122–3.

14. Wu Y. F., Xu H. M., Chen J. Q. Relations of proliferative activities of gastric carcinoma cells to lymphatic involvement, venous invasion and prognosis. Chin Med J. (Engl). 2004;117 (10):1530–5.

15. Veenhuizen R. В., Marijnissen J. P., Kenemans P., Ruevekamp-Helmers M. C., ‘t Mannetje L. W., Helmerhorst T. J., et al. Intraperitoneal photodynamic therapy of the rat CC531 adenocarcinoma. Br J Cancer. 1996;73:1387–92. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074484/

16. Yonemura Y., Fujimura T., Nishimura G., Falla R., Sawa T., Katayama K., et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery. 1996;119 (4):437–44. DOI: http://dx.doi.org/10.1016/S0039–6060(96)80145–0

17. Gilly F. N., Beaujard A., Glehen O., Grandclement E., Caillot J. L., Francois Y. Рeritonectomy combined with intraperitoneal chemohypertermia in abdominal cancer with peritoneal carcinomatosis phase I–II stady. Anticancer Res. 1999;19:2317–21.

18. Glehen O., Mithieux F., Osinsky D., Beaujard A. C., Freyer G., Guertsch Ph., et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: a phase II study. J Clin Oncol. 2003 Mar 1;21 (5):799–806. DOI: 10.1200/JCO.2003.06.139

19. Sugarbaker P. H. Hyperthermic intraoperative intraperitoneal chemotherapy for the treatment of resectable gastric cancer. 4th International gastric cancer congress. 2001, New York. P.336.

20. Verwaal V. J., Van Ruth S., De Bree E., Van Slooten G. W., Van Tinteren H., Boot H., et al. Randomized trial of cytoreduction and hyperthermicintraperitoneal chemotherapy versus systemic chemotherapyand palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003 Oct 15;21 (20):3737– 43. DOI: 10.1200/JCO.2003.04.187

21. Stranadko E. F., Tolstykh P. I. Fotodinamicheskaya terapiya neopukholevykh zabolevanii. Aktual’nye aspekty lazernoi meditsiny [Photodynamic therapy of nonneoplastic diseases. Actual aspects of laser medicine]. Collection of scientific works. Moscow, 2002, pp. 365–6. (In Russian).

22. Filonenko E. V. Fluorescence diagnostics and photodynamic therapy: justification of applications and opportunities in oncology. Photodynamic therapy and photodiagnostics. 2014;1:3–7. (In Russian).

23. Douglass H. O., Nava H. R., Weishaupt K. R., Boyle D., Sugerman M. G., Halpern E., et al. Intra-abdominal applications of hematoporphyrin photoradiation therapy. Adv Exp Med Biol. 1983;160:15–21.

24. Tochner Z., Mitchell J. B., Smith P., Harrington F., Glatstein E., Russo D., et al. Photodynamic therapy of ascites tumours within the peritoneal cavity. Br J Cancer. 1986;53:733–6. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001401/

25. Veenhuizen R. В., Marijnissen J. P., Kenemans P., Ruevekamp-Helmers M. C., ‘t Mannetje L. W., Helmerhorst T. J., et al. Intraperitoneal photodynamic therapy of the rat CC531 adenocarcinoma. Br J Cancer. 1996;73:1387–92. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074484/

26. Molpus K. L., Kato D., Hamblin M. R., Lilge L., Bamberg M., Hasan T. Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. Cancer Res. 1996;56:1075–82. Available at: http://cancerres.aacrjournals.org/content/56/5/1075

27. Veenhuizen R. В., Ruevekamp-Helmers M. C., Helmerhorst T. J., Kenemans P., Mooi W. J., Marijnissen J. P., et al. Intraperitoneal photodynamic therapy in the rat: comparison of toxicity profiles for photofrin and MTHPC. Int J Cancer. 1994;59:830–6.

28. Tochner Z., Mitchell J. B., Hoekstra H. J., Smith P., DeLuca A. M., Barnes M., et al. Photodynamic therapy of the canine peritoneum: normal tissue response to intraperitoneal and intravenous photofrin followed by 630 Nm light. Lasers Surg Med. 1991;11 (2):158–64. DOI: 10.1002/lsm.1900110210

29. DeLaney T. F., Sindelar W. F., Thomas G. F., DeLuca A. M., Taubenberger J. K. Tolerance of small bowel anastomoses in rabbits to photodynamic therapy with dihematoporphyrin ethers and 630 nm red light. Lasers Surg Med. 1993;13:664–71. DOI: 10.1002/lsm.1900130611

30. Major A. L., Rose G. S., Svaasand L. O., Lüdicke F., Campana A., van Gemert M. J. Intraperitoneal photodynamic therapy in the Fischer 344 rat using 5‑ami-nolevulinic acid and violet laser light: a toxicity study. J Photochem Photobiol B. 2002 Mar;66 (2):107–14. DOI: http://dx.doi.org/10.1016/S1011–1344 (01)00249–4

31. Griffin G. M., Zhu T., Solonenko M., Del Piero F., Kapakin A., Busch T. M., et al. Preclinical evaluation of motexafin lutetium- mediated intraperitoneal photodynamic therapy in a canine model. Available at: Clin Cancer Res. 2001 Feb;7 (2):374–81. http://clincancerres.aacrjournals.org/content/7/2/374.long

32. Ross H. M., Smelstoys J. A., Davis G. J., Kapatkin A. S., Del Piero F., Reineke E., et al. Photodynamic Therapy with motexafin lutetium for rectal cancer: a preclinical model in the dog. Surg Res. 2006;135:323–30. DOI: 10.1016/j.jss.2006.01.020

33. DeLaney T. F., Sindelar W. F., Tochner Z., Smith P. D., Friauf W. S., Thomas G., et al. Phase I Study of Debulking Surgery and Photodynamic Therapy for disseminated intraperitoneal tumors. Int J Radiat Oncol Biol Phys. 1993;25:445–57. DOI: http://dx.doi.org/10.1016/0360–3016 (93)90066–5

34. Sindelar W. F., DeLaney T. F., Tochner Z., Thomas G. F., Dachoswki L. J., Smith P. D., et al. Technique of photodynamic therapy for disseminated intraperitoneal malignant neoplasms. phase I study. Arch Surg. 1991;126:318–24. DOI:10.1001/archsurg.1991.01410270062011

35. Sindelar W. et al. Intraperitoneal Photodynamic therapy shows efficacy in phase I trial. Proc Am Soc CIm. Oncol. 1995;14:447.

36. Griffin G. M., Zhu T., Solonenko M., Del Piero F., Kapakin A., Busch T. M., et al. Preclinical evaluation of motexafin lutetium- mediated intraperitoneal photodynamic therapy in a canine model. Clin Cancer Res. 2001;7:374–81. Available at: http://clincancerres.aacrjournals.org/content/7/2/374.long

37. Wilson J. J., Jones H., Burock M., Smith D., Fraker D. L., Metz J., et al. Patterns of recurrence in patients treated with photodynamic therapy for intraperitoneal carcinomatosis and sarcomatosis. Int J Oncol. 2004;24:711–7. DOI: 10.3892/ijo.24.3.711

38. Hendren S. K., Hahn S. M., Spitz F. R., Bauer T. W., Rubin S. C., Zhu T., et al. Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Ann Surg Oncol. 2001;8:65–71.

39. Menon C., Kutney S. N., Lehr S. C., Hendren S. K., Busch T. M., Hahn S. M., et al. Vascularity and uptake of photosensitizer in small human tumor nodules: implications for intraperitoneal photodynamic therapy. Clin Cancer Res. 2001;7:3904–11. Available at: http://clincancerres.aacrjournals.org/content/7/12/3904.long

40. Filonenko Е. V., Vashakmadze L. А., Kirillov N. V., Khomyakov V. М. Intraoperative photodynamic therapy in surgical treatment of gastric cancer (literature review). Sibirskiy onkologicheskiy zhurnal. 2012;2 (50):84–9. (In Russian).

41. Hynes N. E., Lane H. A., ERBB Receptors and Cancer: The complexity of targeted inhibitors. Natl. Rev. Cancer. 2005;5:341–54. DOI: 10.1038/nrc1609

42. Silva С. М. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogens. 2004;23:8017–23. DOI: 10.1038/sj.onc.1208159

43. Moor A. et al. Photoimunotargeting of the epidermal growth factor receptor for the treatment of ovarian cancer. 13th International Congress on Photobiology and 28th Annual Meeting ASP. 2000. p. 166.

44. Tong Z., Singh G., Rainbow A J. Sustained activation of the extracellular signal-regulated kinase pathway protects cells from photofrin-mediated photodynamic therapy. Cancer Res. 2002;62:5528–35. Available at: http://cancerres.aacrjournals.org/content/62/19/5528.long

45. Liu W., Oseroff A. R., Baumann H. Photodynamic therapy causes cross-linking of signal transducer and activator of transcription proteins and attenuation of interleukin‑6 cytokine responsiveness in epithelial cells. Cancer Res. 2004;64:6579–87. DOI: 10.1158/0008–5472.CAN‑04–1580

46. Kengel K., et al. Survival signaling through nuclear epidermal growth factor receptor and STAT3 mediates photodynamic therapy resistance in ovarian and lung cancer cells. Int J Radiat Oncol. Biot Phys. 2007;69 (3):98–9.

47. del Carmen M. G., Rizvi I., Chang Y., Moor A. C., Oliva E., Sherwood M., et al. Synergism of epidermal growth factor receptor- targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. Natl. Cancer Inst. 2005;97:1516–24. DOI: 10.1093/jnci/dji314

48. Hasan Solhan N., Rizvi I., Hasan T. Targeted photodynamic therapy. Users Surg Med. 2006;38:522–31. DOI: 10.1002/lsm.20345

49. Molpus К. L., Hamblin M. R., Rizvi I., Hasan T. Intraperitoneal photoimmunotherapy of ovarian carcinoma xenografts in nude mice using charged photoimmunoconjugates. Gynecol Oncol. 2000;76:397–404. DOI: 10.1006/gyno.1999.5705

50. Verwaal V. J., Van Ruth S., De Bree E., Van Slooten G. W., Van Tinteren H., et al. Randomized trial of cytoreduction and hyperthermicintraperitoneal chemotherapy versus systemic chemotherapyand palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol by American Society of Clinical Oncology. 2003;21:3737–43. DOI: 10.1200/JCO.2003.04.187

51. Roy I., Ohulchanskyy T. Y., Pudavar H. E., Bergey E. J., Oseroff A. R., Morgan J., et al. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J Am Chem Soc. 2003 Jul 2;125 (26):7860–5. DOI: 10.1021/ja0343095

52. Rai P., Chang S. K., Mai Z., Neuman D., Hasan T. Nanotechnology-based combination therapy improves treatment response in cancer models. Proc SPIE. 2009;7380:73801–11.

53. Wilson B. C. Photonic and non-photonic based nanoparticles in cancer imaging and therapeutics. In: Dubowski J, Tanev S, eds. Photon-Based Nanoscience and Nanobiotechnology. Dordrecht, the Netherlands: Springer; 2006, pp. 121–51.